scispace - formally typeset
S

Sándor Lovas

Researcher at Creighton University

Publications -  117
Citations -  3092

Sándor Lovas is an academic researcher from Creighton University. The author has contributed to research in topics: Receptor & Binding site. The author has an hindex of 28, co-authored 114 publications receiving 2894 citations. Previous affiliations of Sándor Lovas include University of Düsseldorf & Wistar Institute.

Papers
More filters
Journal ArticleDOI

The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding.

TL;DR: The data suggest that drosocin and pyrrhocoricin binding prevents the frequent opening and closing of the multihelical lid over the peptide-binding pocket of DnaK, permanently closes the cavity, and inhibits chaperone-assisted protein folding.
Journal ArticleDOI

Interaction between Heat Shock Proteins and Antimicrobial Peptides

TL;DR: All three antibacterial peptides strongly interacted with two bacterial lipopolysaccharide preparations in solution, indicating that the initial step of the bacterial killing cascade proceeds through LPS-mediated cell entry.
Journal ArticleDOI

Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain.

TL;DR: It is proposed based on the biological activity of lampreys GnRH-III in these studies and the occurrence of this peptide during metamorphosis in lampreys, that both lamprey Gn RH-I and -III are neurohormones involved in reproduction in lamprey.
Journal ArticleDOI

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment

TL;DR: Its biological activity, superior stability in biological fluids as well as acceptable toxicity profile indicate that the peptidomimetic represents a true lead compound for pharmaceutical development to replace low adiponectin levels in cancer and other malignancies.
Journal ArticleDOI

Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin.

TL;DR: Findings highlighted pyrrhocoricin's suitability for combating intracellular pathogens and raised the possibility that the proline-rich antibacterial peptides can deliver drug leads into mammalian cells.